Business Wire

GenSight Biologics Reports Clinically Meaningful Vision Improvement is Maintained 4 Years After One-time Treatment with LUMEVOQ ® Gene Therapy

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies ...
The American Journal of Managed Care

Study Evaluates Efficacy of At-Home Visual Acuity Test

Study results, published in JAMA Ophthalmology, showed the Home Acuity Test can be used to measure visual acuity by telephone for a wide range of outpatients with diverse conditions under the care of ...
Business Wire

GenSight Biologics Announces Publication of Results from the REALITY LHON Natural History Study in the Journal Eye

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing ...